ClinicalTrials.Veeva

Menu

Myopia Progression and the Effect of 7-Methylxanthine

T

Trier Research Laboratories

Status and phase

Unknown
Phase 2

Conditions

Myopia

Treatments

Drug: 7-methylxanthine

Study type

Interventional

Funder types

Other

Identifiers

NCT00263471
2612-2320

Details and patient eligibility

About

7-methylxanthine has been shown to increase the concentration and thickness of collagen fibrils in rabbit sclera. Deficient collagen in the sclera may be the cause of progression of childhood myopia. The study hypothesis is that treatment with 7-methylxanthine will stabilize the sclera and prevent further progression of myopia.

Full description

Participants are given tablets of 7-methylxanthine 400 mg per day or placebo tablets for 12 months. Axial length, cycloplegic refraction and corneal curvature is measured, as well as weight, height, blood pressure and heart rate. The participants are interviewed about possible CNS, gastrointestinal, or cardiopulmonal side effects.

Sex

All

Ages

8 to 13 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per year.

Exclusion criteria

Severe general ailment (for example diabetes, epilepsy, psychiatric disease) Eye diseases (for example cataract, keratoconus, chronic iritis, glaucoma)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems